Veracyte, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VCYT research report →
Range $47 – $66
Price Chart
About the company
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
- CEO
- Marc Stapley
- IPO
- 2013
- Employees
- 755
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on VCYT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.52B
- P/E
- 51.12
- Fwd P/E
- 31.29
- PEG
- 0.32
- P/S
- 8.34
- P/B
- 3.35
- EV/EBITDA
- 38.25
- Div Yield
- 0.00%
- Gross Margin
- 71.31%
- Op Margin
- 12.45%
- Net Margin
- 16.25%
- ROE
- 6.86%
- ROIC
- 4.73%
Latest fiscal year · YoY change
- Revenue
- $517.14M+16.0%
- Gross Profit
- $360.05M+20.8%
- Op Income
- $74.15M
- Net Income
- $66.35M+174.9%
- EPS
- $0.84+162.5%
- OCF Growth
- +81.5%
- FCF Growth
- +98.5%
- 52W High
- $60.91
- 52W Low
- $22.92
- 50D MA
- $51.83
- 200D MA
- $41.39
- Beta
- 1.93
- RSI (14)
- 52
- Avg Volume
- 1.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the VCYT Q1 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 99.4%
- Shares Outstanding
- 79.79M
- Float Shares
- 79.28M
of shares held by institutions
340 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VCYT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Feb 18, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 16, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 10, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 23, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 8, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 29, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 17, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 24, 19 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 12, 19 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 6, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.17M | ▲ 43.82K |
| Vanguard Group Inc | 8.50M | ▼ 77 |
| Fmr LLC | 7.76M | ▲ 2.03M |
| Artisan Partners Limited Partnership | 5.50M | ▼ 766.67K |
| State Street Corp | 5.04M | ▲ 682.68K |
| Ark Investment Management LLC | 3.05M | ▼ 833.73K |
| Dimensional Fund Advisors LP | 2.88M | ▲ 80.61K |
| Wellington Management Group Llp | 2.56M | ▲ 521.90K |
| First Trust Advisors LP | 2.12M | ▲ 833.54K |
| Geode Capital Management, LLC | 1.96M | ▲ 56.21K |
| Bank Of America Corp | 1.45M | ▲ 185.93K |
| Gw&K Investment Management, LLC | 1.44M | ▲ 297.24K |
Held by 395 ETFs
Biggest fund positions in VCYT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | EASTHAM KARIN | sell | 3,200 |
| Jun 18, 26 | EASTHAM KARIN | sell | 529 |
| Jun 11, 26 | EASTHAM KARIN | other | 5,272 |
| Jun 11, 26 | JONES EVAN/ FA | other | 5,272 |
| Jun 11, 26 | Shafer David Brent | other | 5,272 |
| Jun 11, 26 | Barr Eliav | other | 5,272 |
| Jun 11, 26 | EPSTEIN ROBERT S | other | 5,272 |
| Jun 11, 26 | Holstein Jens | other | 5,272 |
| Jun 11, 26 | Bhanji Muna | other | 5,272 |
| Jun 11, 26 | Miller Thomas F. | other | 5,272 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VCYT coverage
Recent articles, reports, and earnings notes.
No research on VCYT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VCYT report →First Trust Advisors LP Buys 833,543 Shares of Veracyte, Inc. $VCYT
defenseworld.net · Jul 26
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
zacks.com · Jul 23
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
fool.com · Jul 23
Fifth Third Bancorp Purchases 52,043 Shares of Veracyte, Inc. $VCYT
defenseworld.net · Jul 23
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
fool.com · Jul 21
Amova Asset Management Americas Inc. Has $33.63 Million Holdings in Veracyte, Inc. $VCYT
defenseworld.net · Jul 21
Artisan Mid Cap Fund Q2 2026 Performance Review
seekingalpha.com · Jul 15
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on VCYT?